Trial of Optimal Personalised Care After Treatment—Gynaecological Cancer (TOPCAT-G): A Randomized Feasibility Trial

Val Morrison, Llinos H. Spencer, Nikki Totton, Kirstie Pye, Yeo Seow Tien, Caryl Butterworth, Liz Hall, Rhiannon Whitaker, Rhiannon Tudor Edwards, Laura J. Timmis, Zoe Hoare, Richard D. Neale, Clare Wilkinson, Simon Leeson

Research output: Contribution to journalArticlepeer-review


Objective: This study aimed to evaluate the feasibility of completing a parallel-group randomized controlled trial to compare usual follow-up care for women who have completed treatment of gynecological cancer against a nurse-led telephone intervention, known as Optimal Personalised Care After Treatment—Gynaecological.

Methods: The unblinded trial aimed to recruit patients who had completed treatment of cervical, endometrial, epithelial ovarian, or vulval cancer within the previous 3 months at 3 North Wales hospitals. We randomized participants to either usual hospital-based follow-up or specialist nurse–led telephone education, empowerment, and structured needs assessment follow-up. The primary outcomes assessed the feasibility of running a larger trial including patient eligibility, recruitment and retention rates, and outcome measure completion. Secondary outcomes were generic and health-related quality of life and a patient self-report health service use (Client Service Receipt Inventory) data collected at 3 time points (baseline, 3 months, and 6 months).

Results: Of the 58 women screened, 44 were eligible (76%) and 24 (55%) were recruited and randomized (12:12 to control and intervention, respectively). One participant was lost to follow-up. Recruited participants had a mean (SD) age of 60 (11.2) years and were approximately 5 months from their initial diagnosis (mean [SD], 159 [58] days). Seventeen (71%) of the participants had an endometrial cancer diagnosis. All outcome measure completion rates exceeded 96%. Although not a core feasibility objective, analyses of outcome measures indicated positive changes in quality of life and well-being within the Optimal Personalised Care After Treatment—Gynaecological group; exploratory cost consequence analysis indicated that the nurse-led intervention had a mean total service use cost of £27 per patient (bootstrapped 95% confidence interval, −£290 to £240) lower than did the standard care group.

Conclusion: Eligibility, recruitment, and retention rates as well as outcome measure completion showed that the trial is feasible.
Original languageEnglish
Pages (from-to)401
Number of pages411
JournalInternational Journal of Gynecological Cancer
Issue number2
Publication statusE-pub ahead of print - 1 Feb 2018


  • optimised personal care
  • treatment
  • gynaecological cancer
  • feasibility trial
  • telephone follow-up


Dive into the research topics of 'Trial of Optimal Personalised Care After Treatment—Gynaecological Cancer (TOPCAT-G): A Randomized Feasibility Trial'. Together they form a unique fingerprint.

Cite this